Johnson & Johnson (NYSE:JNJ) Shares Down 0.2%

Johnson & Johnson (NYSE:JNJ - Get Free Report)'s share price dropped 0.2% during mid-day trading on Tuesday . The stock traded as low as $150.87 and last traded at $150.96. Approximately 1,016,304 shares changed hands during mid-day trading, a decline of 86% from the average daily volume of 7,314,583 shares. The stock had previously closed at $151.27.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of recent research reports. Cantor Fitzgerald reissued an "overweight" rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Monday, May 6th. HSBC raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating and increased their price objective for the company from $169.00 to $170.00 in a research report on Thursday, April 18th. StockNews.com raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Tuesday, February 6th. Morgan Stanley cut their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set an "equal weight" rating on the stock in a report on Wednesday, April 17th. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $175.00 price objective on shares of Johnson & Johnson in a report on Thursday, May 16th. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $175.86.

Johnson & Johnson Price Performance

The firm has a 50-day simple moving average of $151.88 and a 200-day simple moving average of $155.12. The firm has a market capitalization of $364.01 billion, a PE ratio of 9.43, a PEG ratio of 2.55 and a beta of 0.55. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $0.07. The company had revenue of $21.38 billion during the quarter, compared to analyst estimates of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The firm's quarterly revenue was up 2.3% compared to the same quarter last year. During the same period in the previous year, the business posted $2.68 earnings per share. As a group, equities analysts forecast that Johnson & Johnson will post 10.64 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Monday, May 20th. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.19. This represents a $4.96 annualized dividend and a yield of 3.28%. Johnson & Johnson's payout ratio is 29.68%.

Institutional Investors Weigh In On Johnson & Johnson

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. 4J Wealth Management LLC boosted its holdings in Johnson & Johnson by 2.2% in the 4th quarter. 4J Wealth Management LLC now owns 2,835 shares of the company's stock worth $444,000 after buying an additional 62 shares during the period. My Personal CFO LLC boosted its stake in shares of Johnson & Johnson by 1.4% in the fourth quarter. My Personal CFO LLC now owns 4,550 shares of the company's stock worth $713,000 after acquiring an additional 62 shares during the period. Eagle Strategies LLC grew its position in shares of Johnson & Johnson by 1.8% during the fourth quarter. Eagle Strategies LLC now owns 3,589 shares of the company's stock worth $563,000 after purchasing an additional 63 shares in the last quarter. Clearview Wealth Advisors LLC raised its stake in Johnson & Johnson by 1.5% during the 4th quarter. Clearview Wealth Advisors LLC now owns 4,373 shares of the company's stock valued at $685,000 after purchasing an additional 64 shares during the period. Finally, Brookmont Capital Management boosted its stake in Johnson & Johnson by 0.4% in the 4th quarter. Brookmont Capital Management now owns 14,852 shares of the company's stock worth $2,328,000 after purchasing an additional 64 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.